Dad of two claims pioneering treatment in Prague saved his life – Irish Mirror
By the Irish Mirror The 64-year-old, from Kinsale, Co Cork has ‘never looked back’ An engineer who was diagnosed with prostate cancer claims pioneering treatment abroad saved his life. Eamon Jackson flew 1,000 miles to Prague for proton beam therapy and is now free of the disease. Dad-of-two Eamon monitored his PSA levels – a […]
Advanced Oncotherapy #AVO – GPSL Research on Advanced Oncotherapy Plc
Free to access research and investor meetings in a post-MiFID2 world Advanced Oncotherapy (AVO-GB): Revamped particle therapy story Recommendation: OUTPERFORM (from NON-RATED) Target Price: 155p (from NIL) Current Price: 46p Click here for full PDF version KEY TAKEAWAY We upgrade AVO to OUTPERFORM with a fair value of 155 GBp. The company […]
Proton RT for Prostate Cancer Has Reduced Toxicity, Higher Cost vs Other RT Options – Modern Medicine Network
by Dave Levitan, Prostate Cancer, Genitourinary Cancers First published Mar 26, 2018 View original article here Proton radiation therapy offers some reduced toxicity over intensity-modulated radiotherapy (IMRT) in patients under the age of 65 with prostate cancer, but its cost is nearly twice that of IMRT, according to a new analysis. Stereotactic body radiotherapy (SBRT) […]
Advanced Oncotherapy #AVO – Peter Gyllenhammar AB shareholding
TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii: Advanced Oncotherapy plc 1b. Please indicate if the issuer is […]
Brand CEO Alan Green talks Prairie Mining #PDZ, Powerhouse Energy #PHE & Advanced Oncotherapy #AVO on Vox Markets podcast
Brand CEO Alan Green talks Prairie Mining #PDZ, Powerhouse Energy #PHE & Advanced Oncotherapy #AVO with Justin Waite on the Vox Markets podcast. Interview starts 29 minutes 43 seconds in.
Advanced Oncotherapy #AVO – Update on Distribution Agreement
Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that discussions between Yantai Cipu, through its affiliated entity Liquid Harmony, and a major medical equipment and pharmaceutical distribution company in China are continuing beyond the previously announced date of 31 March 2018. As announced on 16 February 2018, Yantai Cipu informed […]
Dosimetric comparison to the heart and cardiac substructure in a large cohort of esophageal cancer patients treated with proton beam therapy or Intensity-modulated radiation therapy
Dosimetric comparison to the heart and cardiac substructure in a large cohort of esophageal cancer patients treated with proton beam therapy or Intensity-modulated radiation therapy. Author information Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, United States; Department of Radiology, Keio University School of Medicine, Tokyo, Japan. Abstract PURPOSE: To […]
Advanced Oncotherapy #AVO – Hardman & Co Research: Confidence greatly boosted
Confidence greatly boosted: Advanced Oncotherapy (AVO) is focused on delivering a more affordable, novel, proton-based radiotherapy system, based on technology developed originally at the world-renowned CERN. Major technical milestones were achieved in 2017 and the company remains on track with its development plan. Confidence has been enhanced significantly with integration of the first three structures and […]
Therapeutic particles – CERN Courier
Therapeutic particles by Virginia Greco, CERN. The accelerator technology underpinning Europe’s first particle-therapy facilities, driven by the TERA Foundation during the past 25 years, is poised to unleash new treatment modes in more compact ways. Last September the TERA Foundation – dedicated to the study and development of accelerators for particle therapy – celebrated its 25th […]
Advanced Oncotherapy #AVO – Holdings in Company
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii Advanced Oncotherapy Plc 2 Reason for the notification (please tick the appropriate box or boxes): An acquisition or disposal of voting rights An acquisition or disposal of qualifying financial instruments which […]